Skip to main content
. 2021 May 16;24(4):780–789. doi: 10.1007/s10120-021-01196-3

Fig. 1.

Fig. 1

Antibody–drug conjugate functional mechanism and bystander antitumor effect of trastuzumab deruxtecan. T-DXd trastuzumab deruxtecan; HER2 human epidermal growth factor receptor 2